Ersilia Varone
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Pyrazolone-based ERO1 inhibitors in ERO1-driven triple-negative breast cancer and SEPN1-related myopathy: Structure-activity relationship and therapeutic potential.
Journal: Pharmacological research
Published: August 26, 2025
Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment.
Journal: Cell death & disease
Published: September 18, 2024
ERO1 alpha deficiency impairs angiogenesis by increasing N-glycosylation of a proangiogenic VEGFA.
Journal: Redox biology
Published: July 18, 2022
Endoplasmic reticulum oxidoreductin 1-alpha deficiency and activation of protein translation synergistically impair breast tumour resilience.
Journal: British journal of pharmacology
Published: January 17, 2022
Crosstalk between ERO1α and ryanodine receptor in arsenite-dependent mitochondrial ROS formation.
Journal: Biochemical pharmacology
Published: December 13, 2021
Functional organization of the endoplasmic reticulum dictates the susceptibility of target cells to arsenite-induced mitochondrial superoxide formation, mitochondrial dysfunction and apoptosis.
Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
Published: July 14, 2021
Selenoprotein N is an endoplasmic reticulum calcium sensor that links luminal calcium levels to a redox activity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 21, 2020
Defective endoplasmic reticulum-mitochondria contacts and bioenergetics in SEPN1-related myopathy.
Journal: Cell death and differentiation
Published: March 04, 2020
Last Updated: 09/26/2026